SRR2016974
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.470
- G2M_CHECKPOINT+0.420
- MITOTIC_SPINDLE+0.290
- INTERFERON_ALPHA_RESPONSE+0.210
- PROTEIN_SECRETION+0.200
- SPERMATOGENESIS+0.190
- INTERFERON_GAMMA_RESPONSE+0.160
- IL6_JAK_STAT3_SIGNALING+0.130
- ANDROGEN_RESPONSE+0.120
- MYC_TARGETS_V2+0.100
Top 10 suppressed
- ANGIOGENESIS-0.460
- NOTCH_SIGNALING-0.450
- HYPOXIA-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- CHOLESTEROL_HOMEOSTASIS-0.410
- WNT_BETA_CATENIN_SIGNALING-0.380
- GLYCOLYSIS-0.370
- MYOGENESIS-0.320
- OXIDATIVE_PHOSPHORYLATION-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10899995 | — | — | 0.823 |
| 2 | 550c15f6-55cf-4928-bc62-bb28bc5672da | — | — | 0.803 |
| 3 | 0f095e03-de38-4be9-874c-c58893e031d9 | — | — | 0.798 |
| 4 | SRR12202426 | — | — | 0.786 |
| 5 | SRR12475138 | — | — | 0.780 |
| 6 | TCGA-AR-A24H-01A-11R-A169-07 | — | B | 0.779 |
| 7 | TCGA-DK-A3IV-01A-22R-A21D-07 | — | — | 0.773 |
| 8 | MBCProject_0054_T1B_RNA | — | B | 0.772 |
| 9 | TCGA-D8-A147-01A-11R-A115-07 | — | E | 0.769 |
| 10 | 6b375859-116e-4a5e-b5b4-994a56cc9a75 | — | — | 0.766 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.070 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.010 | Idelalisib | — uncovered |